A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
Latest Information Update: 11 Jul 2025
At a glance
- Drugs IMVT-1402 (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Sponsors Immunovant
Most Recent Events
- 06 Jun 2025 Number of treatment arms has been changed from 3 to 2.
- 20 May 2025 Status changed from planning to recruiting.
- 03 May 2025 New trial record